文档介绍：糖尿病肾病临床治疗疗效研究
本文采集自网络,本站发布的论文均是优质论文,版权和著作权归原作者所有。
[摘要] 目的探?黄葵胶囊联合缬沙坦治疗糖尿病肾病临床疗效。方法方便选取该院2014年5月―2016年5月期间收治的86例糖尿病肾病患者,依据随机法划分为参照组与研究组各43例。参照组43例患者给予缬沙坦等常规治疗,研究组43例患者在此基础上加用黄葵胶囊进行治疗。对两组患者临床指标及临床疗效进行比较。结果治疗后研究组TC为(±)mmol/L,明显低于参照组的(±)mmol/L,差异有统计学意义(t= 9,P= 0<);治疗后研究组TG为(2±)mmol/L,明显低于参照组的(±)mmol/L,差异有统计学意义(t= 5,P= 1<);治疗后研究组UAER为(±)μg/min,明显低于参照组的(±)μg/min,差异有统计学意义(t= 1,P= 0<);%,%,差异有统计学意义(χ2= 3,P= 9<)。结论对糖尿病肾病患者应用黄葵胶囊联合缬沙坦治疗可取得良好的效果,且不良反应少,值得推广。
[关键词] 黄葵胶囊;缬沙坦;糖尿病肾病
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2017)04(b)-0130-03
Research on Curative Effect of Clinical Treatment of Diabetic Nephropathy
LI Ying-lan
Department of Medicine, Yucheng Hospital of Traditional Chinese Medicine, Yucheng, Shandong Province, 251200 China
[Abstract] Objective To discuss the clinical curative effect of Abelmosk capsule and valsartan in treatment of diabetic nephropathy. Methods 86 cases of patients with diabetic nephropathy admitted and treated in our hospital from May 2014 to May 2016 were convenient selected and randomly divided into two groups with 43 cases in each, the control group adopted the routine treatment of valsartan, while the research group adopted the f abelmosk capsule and valsartan treatment, and the clinical index and clinical cura